Roche announced the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States (US) with neovascular or ?wet? age-related macular degeneration (nAMD), following the end of a voluntary recall. The US Food and Drug Administration (FDA) has approved a post-approval supplement to the Biologics License Application for Susvimo, reflecting component-level updates made to the ocular implant and refill needle.

Roche will work to make Susvimo available in the US to retina specialists and their patients with nAMD in the coming weeks. Susvimo provides continuous delivery of a customised formulation of ranibizumab via the Port Delivery Platform, while other currently approved treatments may require multiple eye injections per year. The Susvimo implant is surgically inserted into the eye during a one-time, outpatient procedure and is refilled once every six months using a specifically designed needle, which introduces a customised formulation of ranibizumab directly into the device.

Susvimo was approved by the FDA in 2021. The following year, Roche voluntarily recalled the ocular implant, insertion tool and initial fill kit in the US following test results that showed some implants did not perform to Roche?s standards. Roche has since updated the Susvimo implant and refill needle, and testing confirmed that they now meet these performance standards.

Manufacturing process improvements were also implemented. Roche is committed to making this innovative drug delivery system available around the world. This is one of multiple options Roche continues to develop to meet the needs of people living with nAMD and other prevalent eye conditions, including diabetic macular edema.